- Home
- ESLA vs NTRB Comparison
ESLA vs NTRB Comparison
Compare ESLA & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | NTRB |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 36.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESLA | NTRB |
|---|---|---|
| Price | $0.73 | $4.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 23.6K | 20.3K |
| Earning Date | 05-26-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.68 | $2.80 |
| 52 Week High | $3.15 | $8.63 |
Technical Indicators
Market Signals| Indicator | ESLA | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 77.36 |
| Support Level | N/A | $4.23 |
| Resistance Level | N/A | $4.98 |
| Average True Range (ATR) | 0.00 | 0.30 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 0.00 | 68.73 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.